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Abstract
Aim: The complex pathobiology of traumatic brain injury (TBI) offers numerous targets for potential
neuroprotective agents. We evaluate the clinical beneﬁt after creatine (Cr) administration in children
and adolescents
Methods: A prospective, randomized, comparative, open- labelled pilot study of the possible
neuroprotective effect of Cr was carried out on 39 children and adolescents, aged between 1 and
18 years of age, with TBI. The Cr was administered for 6 months, at a dose of 0.4 g/kg in an oral
suspension form every day. For categorical variables, we used the Chi-square test to identify
differences between controls and cases. Statistical signiﬁcance was deﬁned as a p-value < 0.05 and
not statistically signiﬁcant if p-value > 0.1.
Results: The administration of Cr to children and adolescents with TBI improved results in several
parameters, including duration of post traumatic amnesia (PTA), duration of intubation, intensive care
unit stay. Signiﬁcant improvement was recorded in the categories of headache (p < 0.001), dizziness
(p = 0.005) and fatigue (p < 0.001), aspects in all patients. No side effects were seen due to Cr
administration.
Conclusion: More speciﬁc examinations including brain spectroscopy for in vivo evaluation of Cr can be done, in
order to draw conclusions for the optimal duration and manner of Cr supply, as well as its possible role for the
prevention of TBI complications, in double blind studies.
INTRODUCTION
The most common cause of death and disability after severe
trauma in childhood is traumatic brain injury (TBI). Of all
trauma deaths, 25% are caused by head injury (1). Much is
yet to be learned regarding the effects of severe head trauma
onbraindevelopment,butavailablestudiessuggestthatneu-
ropsychiatric recovery after significant head injury takes a
long time following resolution of the immediate effects of
the injury.
Functional deficits result from primary and secondary
mechanisms after TBI. The primary damage occurs at the
time of impact and results from the mechanical insult itself.
The secondary injury, defined as cellular damage not im-
mediately apparent after the trauma but developing within
minutes, hours or even days, seems to be related to mito-
chondria dysfunction associated with the disruption in cel-
lular calcium homeostasis that is known to occur after TBI.
Maintenance of cellular calcium homeostasis is intimately
related to adenosine triphosphate (ATP) use and synthesis,
whicharekeytoproperbrainfunctioning.Enhancedneuron
survival may be improved by providing an adequate supply
of ATP immediately after trauma (2).
Creatine ([Cr] a-methyl-guanidinoacetic acid) is an amino
acid endogenously produced from glycine, methionine and
arginine in the liver, kidney and pancreas (1). Cr supplemen-
tation increases intramuscular and cerebral stores with both
Cr, and its phosphorylated form, phosphocreatine [PCr] (3).
The increase of these stores may offer therapeutic benefits
bystimulatingproteinsynthesisorreducingproteindegrada-
tion, stabilizing biological membranes and preventing ATP
depletion, which occurs in patients with TBI (4,5). Recent
findings in animal models have demonstrated that Cr af-
fords significant neuroprotection against experimental brain
injury (6,7).
Based on these experimental facts, we studied administra-
tion of Cr to patients with TBI (8–13).
SUBJECTS AND METHODS
The institutional ethics committee of the University Hospi-
tal of Heraklion approved the study protocol. A prospec-
tive study was conducted in the Paediatric Surgical
Department of Crete and Thessaloniki from February 2000
to March 2004. Thirty-nine children and adolescents were
enrolled after obtaining informed consent from their par-
ents. They were randomized to study and control groups,
withthestudygroupreceivingCrusingGlasgowComaScale
(GCS) scores as the randomization factor (3–5 vs. 6–9).
Pearson’sChi-squaretestshowedthatthereisnostatistically
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significant difference between the two groups p = 0.835.
We assessed power estimation for categorical variables
(disability or death vs. good recovery). Initial considera-
tions were: Type I error was set at 0.05 and 20 patients per
arm were selected. The probability for a disability outcome
was set at 85%. This percentage was estimated from previ-
ously published studies (14–16). The disability outcome for
Cr group was set at 0.50. The power of this estimation was
calculated at 66, 8%.
Entry and exclusion criteria
Patients eligible for the study had to satisfy the following
inclusion criteria:
1. All patients should have age between 1 and 18 years,
2. GCS should be between 3 and 9 on admission,
3. a paediatric trauma score (PTS) should be between −4
and 12 on admission and
4. treatment could be initiated within 4 h from the time of
injury.
Exclusion criteria were: 1. history of previous admission
to hospital for head injury, 2. known psychiatric disorder
or mental retardation, 3. received other medication within
30 days of enrolment. In general, patients were admitted di-
rectly to the hospital within 1–4 h after injury. The GCS and
PTSwereassessedaspartoftheneurologicalexamination.
Therapy
According to random numbers, patients were allocated to
receive either Cr at a dosage of 0.4 g/kg in an oral suspension
form every day for 6 months or nothing. Cr was mixed with
water or apple juice then flushed through nasogastric tube
or given with a spoon.
Follow-up
After discharge from the hospital a follow-up was done at
6 months after injury by the same blinded surgeon in each
hospital. During each visit a checklist of complaints was
filled out, together with a structured interview and a neu-
rological examination.
Statistical analysis
A parametric (Student’s t-test) and a nonparametric test
(Mann–Whitney U-test) were used to identify if there were
differences between selected continuous variables in con-
trols and cases.
For categorical variables, we used the Chi-square test to
identify differences between controls and cases. Statistically
significance was defined as a p-value < 0.05, trend towards
significant if 0.05 < p-value < 0.1 and not statistically signif-
icant if p-value > 0.1.
RESULTS
Forty-eight children with TBI were admitted to our hospi-
tals during the study. Three children were not eligible and
the parents of four children refused to have their children
participate in the study. A total of 39 eligible children were
randomly selected.
There were 19 children (patients) in group I (controls) and
20 children in group II (Cr). Four children died during the
time period of the study, (within 3 months), two from each
group.
Twenty of the children in the study group received Cr at
a dosage of 0.4 g/kg in an oral suspension form every day
for 6 months, and 19 children received nothing. There were
no significant differences between the two study groups. The
patient characteristics are given in Table S1.
Using the Chi-square test, there were no statistically sig-
nificant differences between the CT/MRI of brain, con-
comitant injuries, electroencephalogram, whether or not an
operation was carried out, the GCS and the PTS between
the two groups.
Outcome assessment (short term)
The mean duration of intubation, length of stay in intensive
care (ICU), hospital stay and post traumatic amnesia (PTA)
was compared between the two groups and the results are
given in Table S2.
Outcome assessment (long term)
There was a statistically significant difference between the
controls and cases and the groups of ‘headache’ ( 2 =
23.139; df = 1; p < 0.001).
More specifically, the proportion of children having
headache is significantly higher in controls than cases
(93.8% vs. 11.1%), while the proportion of children having
no headache is significantly higher in cases than controls
(88.9% vs. 6.3%). (Fig. 1).
There was a statistically significant difference between the
controls and cases and the groups of ‘dizziness’ ( 2 = 7.886;
df = 1; p = 0.005).
More specifically, the proportion of children having ‘dizzi-
ness’ is significantly higher in controls than cases (56.3% vs.
11.1%) while the proportion of children having no ‘dizzi-
ness’ is significantly higher in cases than controls (88.9% vs.
43.8%; Fig. 2).
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Figure 1 Bar chart for Headache of controls and cases.
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Figure 2 Bar chart for dizziness of controls and cases.
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Figure 3 Bar chart for fatigue of controls and cases.
There was a statistically significant difference between the
controls and cases and the groups of ‘fatigue’ ( 2 = 17.881;
df = 1; p < 0.001).
More specifically, the proportion of children having no
fatigue is significantly higher in cases than controls (88.9%
vs. 17.6%) while the proportions of children having fatigue is
significantly higher in controls than cases (82.4% vs. 11.1%;
Fig. 3).
DISCUSSION
The Cr supplementation in children with TBI represents an
attempt to provide neuroprotection for these children. In
this study, the Cr administration gave encouraging results
in several parameters, including posttraumatic headache,
dizziness and fatigue, which are some of the most common
symptoms after closed head injuries (2–4).
Posttraumatic headache can occur after mild, moderate
or severe craniocerebral trauma. The headache may have
features of usually two types: 1. tension-type headache that
may be daily or episodic, 2. migraine headaches that are
usually more severe lasting hours to days and 3. mixed
headaches, both chronic daily headache and migraines (14).
If the headaches develop within 2 weeks of the event, and
persist for more than several months, we consider this to be
the chronic phase of the posttraumatic headache syndrome
(14,15).Thefactthat,at6monthsfollowup,theCrgrouphad
a statistically significant difference regarding the posttrau-
matic headache, provides evidence that the supply of Cr may
be an adequate preventive treatment even for the rebound-
headaches that may develop from the overuse of analgesic
medications (16), as part of a multidimensional management
approachincludingpharmacologicintervention,physicalre-
habilitation and cognitive behavioural therapy as used in
the adult population (17). Positional vertigo, and particu-
larly Bening Paroxysmal Positional Vertigo (BPPV), is the
most common type of severe dizziness, and it is almost com-
mon after head injury. It is easily recognized by the pattern
of dizziness that is brought only when head is placed in a
certain position. Dizziness can be accompanied by noises in
the ear, fullness or hearing changes as in posttraumatic Me-
niere’s syndrome. Also, it can be accompanied by hearing
loss, a nystagmus or peripheral facial weakness as in tem-
poral bone fracture and labyrinthine concussion. A special-
ized examination is very useful in determining the character
of the dizziness like measurement of balance, searching for
nystagmus related to head and/or neck position or to vibra-
tion of the neck. Finally, in most instances an audiogram and
an MRI scan or CT scan of the inner ear is included in the
laboratory tests (18,19).
Generally, fatigue is defined as a sense of weakness, de-
scribed by patients variously as exhaustion, tiredness, lack of
energy and/or low vitality. It is also important to distinguish
between cognitive/mental fatigue versus physical/somatic
fatigue. Many times, persons with TBI will experience both
ofthesephenomena.Someofthemostimportantcomorbidi-
ties of TBI, especially as they related to their role in generat-
ing fatigue include major depression and/or anxiety disorder
and chronic pain that has clearly been shown to be of high
prevalence after TBI (20).
Cr can play an important role as a neuroprotective agent
for the prevention of these symptoms that are part of the
posttraumatic syndrome, that affect the quality of life of both
children and their families.
How Cr works remains to be determined. Work done in
animal models suggested that the mechanical basis for the
neuroprotective effects of Cr might involve alterations of the
insult-induced depletions of cellular ATP. Chronic ingestion
of Cr results in increased brain levels of PCr (21). Similar
results regarding maintenance of cellular ATP levels have
been demonstrated in animal models receiving Cr before
TBI, particularly the effect of chronic administration of Cr
ameliorated the extent of cortical damage by such as 36% in
mice and 50% in rats (2). Lactate and free fatty acids, which
are markers of secondary cellular injury following TBI, have
been found to be lower in animals treated with Cr before
TBI (3). Other mechanisms underlying this neuroprotec-
tion may involve the maintenance of mitochondrial integrity
(22,23). The Cr action may prevent structural mitochondrial
changes, as was shown in experimental work with adult rat
cardiomyocytes cultured in Cr-deficient medium (24). The
possible beneficial effect of Cr on mitochondrial function is
also demonstrated in different clinical studies about Cr ac-
tion on mitochondriopathies (22,23).
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ThereisnodoubtthatthesupplyofCrtopatientswithTBI
needs further investigation, with more patients in double-
blind studies and with longer follow-up. More specific
examinations including brain spectroscopy for in vivo eval-
uation of Cr can be done, in order to draw conclusions for
the optimal duration and manner of Cr supply, as well as its
possible role for the prevention of TBI complications.
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